Qsemble Capital Management LP lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 17.4% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,800 shares of the company’s stock after acquiring an additional 1,600 shares during the quarter. Johnson & Johnson makes up 1.1% of Qsemble Capital Management LP’s portfolio, making the stock its 8th biggest position. Qsemble Capital Management LP’s holdings in Johnson & Johnson were worth $1,674,000 as of its most recent SEC filing.
Several other large investors have also added to or reduced their stakes in the stock. GW&K Investment Management LLC bought a new position in shares of Johnson & Johnson in the 4th quarter worth approximately $35,000. Dark Forest Capital Management LP raised its holdings in Johnson & Johnson by 1,044.4% in the fourth quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock worth $36,000 after purchasing an additional 188 shares in the last quarter. Ruedi Wealth Management Inc. purchased a new position in Johnson & Johnson during the fourth quarter valued at $42,000. Kepos Capital LP purchased a new stake in shares of Johnson & Johnson in the 4th quarter worth about $45,000. Finally, 25 LLC bought a new position in shares of Johnson & Johnson in the 1st quarter worth about $55,000. Institutional investors own 67.57% of the company’s stock.
Insider Activity at Johnson & Johnson
In other Johnson & Johnson news, insider William Hait sold 14,698 shares of the company’s stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the sale, the insider now owns 87,747 shares in the company, valued at $15,092,484. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In related news, insider William Hait sold 14,698 shares of the stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the sale, the insider now directly owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Kathryn E. Wengel sold 12,465 shares of Johnson & Johnson stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the transaction, the executive vice president now directly owns 65,934 shares in the company, valued at approximately $10,549,440. The disclosure for this sale can be found here. Over the last three months, insiders have sold 47,163 shares of company stock worth $7,928,856. Corporate insiders own 0.20% of the company’s stock.
Johnson & Johnson Stock Up 1.4 %
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings data on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, topping the consensus estimate of $2.62 by $0.18. The firm had revenue of $25.53 billion for the quarter, compared to analysts’ expectations of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. The business’s quarterly revenue was up 6.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.59 EPS. As a group, analysts forecast that Johnson & Johnson will post 10.75 earnings per share for the current year.
Johnson & Johnson Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 7th. Stockholders of record on Monday, August 28th will be paid a $1.19 dividend. The ex-dividend date is Friday, August 25th. This represents a $4.76 annualized dividend and a dividend yield of 2.86%. Johnson & Johnson’s dividend payout ratio (DPR) is 96.36%.
Analyst Upgrades and Downgrades
Several research firms recently commented on JNJ. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Tuesday. JPMorgan Chase & Co. upped their price target on Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a research note on Friday, July 21st. Barclays lifted their price objective on Johnson & Johnson from $171.00 to $175.00 and gave the company an “equal weight” rating in a research note on Monday, July 24th. Atlantic Securities increased their target price on Johnson & Johnson from $167.00 to $170.00 and gave the stock a “neutral” rating in a research note on Friday, August 4th. Finally, TheStreet raised Johnson & Johnson from a “c+” rating to a “b+” rating in a research report on Monday. Eight equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Hold” and an average target price of $171.80.
Get Our Latest Stock Report on Johnson & Johnson
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Read More
- Five stocks we like better than Johnson & Johnson
- Crypto vs Stocks: How to Choose Your Investments
- One of these 5 Pet Care Stocks Can Be the Next Short Squeeze
- What Are Dividends? Buy the Best Dividend Stocks
- 3 High Short Interest Stocks that Investors are Getting Wrong
- Investing in Vaccines 101: How to Invest in Vaccine Stocks
- Retail Theft Rises: Two Ways For Investors To Beat Shrinkage
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
